WO2005116648A3 - Method and reagent kit for evaluation of multidrug-resistance activity - Google Patents

Method and reagent kit for evaluation of multidrug-resistance activity Download PDF

Info

Publication number
WO2005116648A3
WO2005116648A3 PCT/IB2005/051707 IB2005051707W WO2005116648A3 WO 2005116648 A3 WO2005116648 A3 WO 2005116648A3 IB 2005051707 W IB2005051707 W IB 2005051707W WO 2005116648 A3 WO2005116648 A3 WO 2005116648A3
Authority
WO
WIPO (PCT)
Prior art keywords
biological specimen
cells
mdr substrate
mdr
accumulation
Prior art date
Application number
PCT/IB2005/051707
Other languages
French (fr)
Other versions
WO2005116648A2 (en
Inventor
Richard Schwab
Istvan Petak
Balazs Sarkadi
Laszlo Kopper
Gyoergy Keri
Akos Pap
Gergely Szakacs
Laszlo Homolya
Ferenc Jakab
Judit Moldvay
Arnold Feher
Original Assignee
Solvo Biotechnology Inc
Richard Schwab
Istvan Petak
Balazs Sarkadi
Laszlo Kopper
Gyoergy Keri
Akos Pap
Gergely Szakacs
Laszlo Homolya
Ferenc Jakab
Judit Moldvay
Arnold Feher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0401055A external-priority patent/HU0401055D0/en
Priority claimed from HU0401851A external-priority patent/HU0401851D0/en
Application filed by Solvo Biotechnology Inc, Richard Schwab, Istvan Petak, Balazs Sarkadi, Laszlo Kopper, Gyoergy Keri, Akos Pap, Gergely Szakacs, Laszlo Homolya, Ferenc Jakab, Judit Moldvay, Arnold Feher filed Critical Solvo Biotechnology Inc
Priority to HU0700042A priority Critical patent/HUP0700042A2/en
Publication of WO2005116648A2 publication Critical patent/WO2005116648A2/en
Publication of WO2005116648A3 publication Critical patent/WO2005116648A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides an in vitro diagnostic method for detecting multi-drug resistance in a biological specimen comprising a heterogeneous population of discrete cells, said method comprising the steps of contacting a first portion of the biological specimen with MDR substrate derivative and a viability reagent; contacting a second portion of the biological specimen with a general inhibitor of transport protein-mediated cell efflux, the MDR substrate derivative, and the viability reagent; measuring the signal generated by the MDR substrate within the viable cells of said second portion; defining an MDR substrate signal intensity range based on data measured above; determining a first rate of MDR substrate accumulation within a population of cells of said first portion of the biological specimen; determining a second rate of MDR substrate accumulation within a population of cells of said second portion of the biological specimen; and calculating the difference in said first and second rates of MDR substrate accumulation, wherein data showing a reduced MDR substrate accumulation in said populations of cells between said first portion and said second portion is indicative of the presence of multi-drug resistance in said biological specimen.
PCT/IB2005/051707 2004-05-25 2005-05-25 Method and reagent kit for evaluation of multidrug-resistance activity WO2005116648A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HU0700042A HUP0700042A2 (en) 2004-05-25 2005-05-25 Method and reagent kit for evaluation of multidrug-resistance activity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
HUP0401055 2004-05-25
HU0401055A HU0401055D0 (en) 2004-05-25 2004-05-25 Method and reagent kit for evaluation of multidrug-resistance activity
HU0401851A HU0401851D0 (en) 2004-09-15 2004-09-15 Method and reagent kit for evaluation of multidrog-resistance activity
HUP0401851 2004-09-15

Publications (2)

Publication Number Publication Date
WO2005116648A2 WO2005116648A2 (en) 2005-12-08
WO2005116648A3 true WO2005116648A3 (en) 2006-03-30

Family

ID=89985499

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/051707 WO2005116648A2 (en) 2004-05-25 2005-05-25 Method and reagent kit for evaluation of multidrug-resistance activity

Country Status (2)

Country Link
HU (1) HUP0700042A2 (en)
WO (1) WO2005116648A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006945A1 (en) * 1994-08-31 1996-03-07 Sarkadi Balazs Assay and reagent kit for the quantitative in vitro determination in biological specimens of the activity of proteins causing multi-drug resistance in tumors
US6277655B1 (en) * 1994-10-13 2001-08-21 Solvo Biotechnology Assay and reagent kit for evaluation of multi-drug resistance in cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006945A1 (en) * 1994-08-31 1996-03-07 Sarkadi Balazs Assay and reagent kit for the quantitative in vitro determination in biological specimens of the activity of proteins causing multi-drug resistance in tumors
US5872014A (en) * 1994-08-31 1999-02-16 Sarkadi; Balazs Assay for multi-drug resistance
US6277655B1 (en) * 1994-10-13 2001-08-21 Solvo Biotechnology Assay and reagent kit for evaluation of multi-drug resistance in cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAOUDAKI MARIA ET AL: "Cyclosporine A augments P-glycoprotein expression in the regenerating rat liver.", BIOLOGICAL AND PHARMACEUTICAL BULLETIN, vol. 26, no. 3, March 2003 (2003-03-01), pages 303 - 307, XP002354012, ISSN: 0918-6158 *
FARRELL RICHARD J ET AL: "High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy", GASTROENTEROLOGY, vol. 118, no. 2, February 2000 (2000-02-01), pages 279 - 288, XP009057101, ISSN: 0016-5085 *
SCHMID I ET AL: "DEAD CELL DISCRIMINATION WITH 7 AMINOACTINOMYCIN D IN COMBINATION WITH DUAL COLOR IMMUNOFLUORESCENCE IN SINGLE LASER FLOW CYTOMETRY", CYTOMETRY, vol. 13, no. 2, 1992, pages 204 - 208, XP009057207, ISSN: 0196-4763 *

Also Published As

Publication number Publication date
WO2005116648A2 (en) 2005-12-08
HUP0700042A2 (en) 2009-03-02

Similar Documents

Publication Publication Date Title
Chowdhury et al. Validation and comparison of two multiplex technologies, Luminex® and Mesoscale Discovery, for human cytokine profiling
WO2005095644A3 (en) Method for recognizing signatures in complex gene expression profiles
WO2001036681A3 (en) Immunological detection of rna:dna hybrids on microarrays
RU2010128653A (en) TILT COMPENSATION
WO2006126008A3 (en) Improved immunoassay methods
WO2007127749A3 (en) Predicting mortality and detecting severe disease
AU2003238869A1 (en) Hybrid microcantilever sensors
JP2011504102A5 (en)
MXPA02010106A (en) Determination of sample volume adequacy in biosensor devices.
WO2008109075A3 (en) Biomarkers and methods for determining sensitivity to ctla-4 antagonists
WO2004046098A3 (en) Method for predicting autoimmune diseases
WO2004025251A3 (en) Cell-based detection and differentiation of disease states
TW200608019A (en) Methods for performing hematocrit adjustment in glucose assays and devices for same
EP1312919A3 (en) Sample volume metering apparatus
WO2007059065A3 (en) Diagnostic method for proteinaceous binding pairs, cardiovascular conditions and preeclampsia
WO2006015387A3 (en) Method for assaying cytolytic activity of target cells
EP2851676A3 (en) Method and assembly for determining the temperature of a test sensor
WO2007133586A3 (en) Systems and methods for developing diagnostic tests based on biomarker information from legacy clinical sample sets
AU2849300A (en) Methods and assay kits for detecting mononuclear cell phenotype
EP2199801A3 (en) Biomarkers for early detection of ovarian cancer
WO2009057695A1 (en) Method for detection of adenoma or cancer by genetic analysis
EP1930730A3 (en) Systems and methods to perform assays for detecting or quantifying analytes
WO2007094805A3 (en) Method for electrocatalytic protein detection
AU2003215467A1 (en) Method and device for predicting cardiovascular events
WO2005059163A3 (en) Methods, compositions, and kits for analysis of enzyme activity in cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase